Vireo GrowthFRA:K95 -5.39%44 Gross Margin % is 55.84% as of Mar. 2026, which is 35% above its 10-year median of 41.42. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 938 Drug Manufacturers companies, Vireo Growth ranks better than 51.81% on this metric.
The historical rank and industry rank for Vireo Growth's Gross Margin % or its related term are showing as below:
FRA:K95'
s Gross Margin % Range Over the Past 10 Years
Min: 24.49 Med: 41.42 Max: 51.09
Current: 49.64
During the past 13 years, the highestGross Margin % of Vireo Growth was 51.09%. The lowest was 24.49%. And the median was 41.42%.
FRA:K95's Gross Margin % is ranked better than 51.81% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs FRA:K95: 49.64
Vireo Growth had a gross margin of 55.84% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vireo Growth was 8.20% per year.
Vireo Growth (FRA:K95) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vireo Growth had a gross margin of 55.84% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vireo Growth Gross Margin % Related Terms
Vireo Growth Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vireo Growth (FRA:K95) has a Gross Margin % of 55.84% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vireo Growth and its competitors. This is 35% above median its historical median of 41.42. Over the past decade, Vireo Growth's Gross Margin % has ranged from 24.49 to 51.09. According to the industry distribution chart, Vireo Growth ranks #452 out of 938 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Vireo Growth's Gross Margin % too high?
Vireo Growth's current Gross Margin % of 55.84% is 35% above median its 10-year median of 41.42. Over the past 10 years, this metric has ranged from a low of 24.49 to a high of 51.09. The Drug Manufacturers industry median Gross Margin % is 48.44. Vireo Growth's value of 55.84% is 15.3% above this industry median. Based on the distribution chart, Vireo Growth ranks #452 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #452 out of 938 companies for Gross Margin %. This puts Vireo Growth in the upper half of its industry. The industry median Gross Margin % is 48.44. Vireo Growth's value of 55.84% is 15.3% above this benchmark. Historically, Vireo Growth's own Gross Margin % has ranged from 24.49 to 51.09 over the past decade. While the company's 10-year median is 41.42 vs. the industry median of 48.44, Vireo Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Gross Margin % of 55.84% is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Gross Margin % is 55.84%, which is 35% above median its own 10-year median of 41.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Gross Margin % is 55.84%, which is 35% above median its 10-year median of 41.42 and 15.3% above the Drug Manufacturers industry median of 48.44. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Gross Margin % is 55.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Gross Margin %: 55.84% (35% above median its 10-year median of 41.42)
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 15.3% above the Drug Manufacturers median (#452 of 938)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
